European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors

The European Commission's approval is based on the CHMP positive opinion Label update comes in response to new biomarker data obtained from the OPUS study DARMSTADT, Germany, Dec. 23, 2013 -- (Healthcare Sales & Marketing Network) -- Merck Serono, t... Biopharmaceuticals, Oncology, RegulatoryMerck Serono, Erbitux, cetuximab, metastatic colorectal cancer, RAS tumor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news